OFIX and SPNE announced a definitive agreement to combine in an all-stock merger of equals. Both companies believe there are meaninful cross-selling revenue synergies, as well as at least $40MM in YoY cost savings to capture over the 3 years following the transaction. The companies have expressed revenue goals of ~$1.0B concluding year 3 post-merger.
Looking forward, the new organization will be a spine and orthopedics company with complementary portfolios in biologics, spinal hardware, bone growth therapies, orthopedic solutions and enabling surgical technologies. SmartTRAK notes that once merged, the new company will be strategically positioned in high-growth emerging technology, including cervical disc replacement with M6-C, enabling technology with 7D’s FLASH Navigation System and OrthoNext preop planning, and with focused development in spine and limb within pediatrics. Additionally, the new company will have a highly competitive offering in the spinal interbody space with its WaveForm 3D and NanoMetalene technologies. Together, the combined company’s biologics portfolio will also represent one of the broadest offerings available in spine and orthopedics.SmartTRAK believes the complimentary product portfolios provide a comprehensive offering and